Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Squadron Capital Management LLC
Form 13F · Q2 2026

Squadron Capital Management LLC

CIK 2050709Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$322M
Reported book value
43
Positions
3
Quarters on record
Top 50
Positions

Squadron Capital Management LLC — holdings

Top 34 positions of 43, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1RLMD Relmada Therapeutics Inc7.3M−13.3%$51M15.8%
2CCCC C4 Therapeutics Inc7.2M+220.0%$34M10.4%
3COGT Cogent Biosciences Inc865,000+9.8%$33M10.4%
4KOD Kodiak Sciences Inc500,000+31.6%$19M6.0%
5RLAY Relay Therapeutics Inc970,000+44.2%$18M5.6%
6ZNTL Zentalis Pharmaceuticals Inc3.7M+1.9%$18M5.6%
7EWTX Edgewise Therapeutics Inc290,000−17.1%$12M3.7%
8MAZE Maze Therapeutics Inc335,000+30.1%$10M3.1%
9IVA Inventiva Sa2.4M+355.1%$9M2.9%
10ANL Adlai Nortye Ltd764,876−39.5%$9M2.7%
11ELVN Enliven Therapeutics Inc160,000—$8M2.5%
12PALI Palisade Bio Inc3.0M+0.0%$6M1.9%
13IKT Inhibikase Therapeutics Inc3.0M−14.3%$6M1.9%
14ADAG Adagene Inc1.2M—$5M1.6%
15FORTE BIOSCIENCES INC Forte Biosciences Inc225,000—$5M1.5%
16INFLARX NV Inflarx Nv2.0M—$4M1.4%
17ASMB Assembly Biosciences Inc160,000—$4M1.4%
18PMN Promis Neurosciences Inc324,977+0.0%$4M1.3%
19CTNM Contineum Therapeutics Inc260,000—$4M1.3%
20CMPS Compass Pathways Plc300,000—$4M1.3%
21DFTX Definium Therapeutics Inc85,000—$4M1.2%
22SLGL Sol-Gel Technologies Ltd52,000+67.7%$4M1.2%
23BIOA Bioage Labs Inc155,000—$4M1.2%
24SCYX Scynexis Inc756,884—$3M1.0%
25PROQR THRAPEUTICS N V Proqr Thrapeutics N V1.5M—$3M0.9%
26RZLT Rezolute Inc403,410—$2M0.7%
27LPCN Lipocine Inc New810,000+80.0%$2M0.6%
28CUE Cue Biopharma Inc50,000—$2M0.5%
29CALC Calcimedica Inc1.2M—$1M0.4%
30QUINCE THERAPEUTICS INC Quince Therapeutics Inc40,375—$734,4210.2%
31KTTA Pasithea Therapeutics Corp1.0M−52.4%$515,4000.2%
32MTRI Inmed Pharmaceuticals Inc325,000—$503,7500.2%
33NMRA Neumora Therapeutics Inc.100,000—$170,0000.1%
34NXTC Nextcure Inc64,464−75.7%$103,1420.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.